Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01920477




Registration number
NCT01920477
Ethics application status
Date submitted
3/07/2013
Date registered
12/08/2013
Date last updated
6/06/2019

Titles & IDs
Public title
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
Scientific title
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Secondary ID [1] 0 0
116910
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pemphigus Vulgaris 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Ofatumumab
Treatment: Other - Placebo

Experimental: Ofatumumab - Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.

Placebo comparator: Placebo - Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.


Treatment: Other: Ofatumumab
Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product

Treatment: Other: Placebo
Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects Who Experienced Sustained Remission on Minimal Steroid Therapy
Timepoint [1] 0 0
Baseline up to approximately 60 weeks
Primary outcome [2] 0 0
Duration of Remission on Minimal Steroid Therapy
Timepoint [2] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [1] 0 0
Percentage of Subjects Achieving Remission on Minimal Steroid Therapy at Week 60
Timepoint [1] 0 0
Week 60
Secondary outcome [2] 0 0
Time to Remission While on Minimal Steroid Therapy by Week 60.
Timepoint [2] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [3] 0 0
Percentage of Subjects Achieving Remission While Off Steroid Therapy by Week 60
Timepoint [3] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [4] 0 0
Number of Days a Subject Maintained Minimal Steroid Therapy by Week 60.
Timepoint [4] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [5] 0 0
Time to Initial Flare/Relapse by Week 60
Timepoint [5] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [6] 0 0
Percentage of Participants With no Flare/Relapse by Week 60
Timepoint [6] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [7] 0 0
Plasma Trough Concentrations of Ofatumumab
Timepoint [7] 0 0
4 hours post baseline, Days 1-4,7,14, Weeks 4,8,12,16,20,24,36,48,52,56, up to approximately 60 weeks
Secondary outcome [8] 0 0
Number of Participants With Values Below Lower Limit of Normal for Immunoglobulin A
Timepoint [8] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [9] 0 0
Number of Participants With Values Below Lower Limit of Normal for Immunoglobulin G
Timepoint [9] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [10] 0 0
Number of Participants With Values Below Lower Limit of Normal for Immunoglobulin M
Timepoint [10] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [11] 0 0
Largest Mean Decrease From Baseline for Immunoglobulin A, G and M
Timepoint [11] 0 0
Baseline up to approximately 60 weeks
Secondary outcome [12] 0 0
Change From Baseline for CD19+ B Cell Count
Timepoint [12] 0 0
Baseline up to approximately 60 weeks

Eligibility
Key inclusion criteria
Inclusion criteria

* Adults (18 through 70 years of age) with clinically-documented diagnosis of PV for >2 months and <10 years.
* History of biopsy consistent with PV (Hematoxylin and Eosin staining and direct immunofluorescence). If no history, a biopsy may be performed during the Screening Period.
* At least 1 previous episode of a failed steroid taper (ie, disease flare/relapse) at a prednisone/prednisolone dose >10 mg/day. The following criteria must have been met as evidence of disease severity at the time of the failed steroid taper: a) A Pemphigus Severity of Clinical Disease score of moderate (2) or severe (3) (may be historical/retrospective assessment). b) Required a treatment change at the time of the failed steroid taper of at least one of the following: i) A steroid increase to >=20 mg/day OR ii) The addition of immunosuppressive/immunomodulatory agent/treatment OR iii) A dose increase of immunosuppressive/immunomodulatory agent/treatment
* Screening anti-Dsg antibodies consistent with a diagnosis of PV (ie, elevated antiDsg3 antibodies).
* Has initiated and received a stable dose of prednisone/prednisolone from a minimum of 20 mg/day (example: 0.25 mg/kg/day for an 80 kg person) up to a maximum of 120 mg/day or 1.5 mg/kg/day (whichever is higher) for >=2 weeks prior to randomization.
* Has exhibited PV disease control, defined as no new lesions for >=2 weeks.
* A female subject is eligible to enter the study if she: Is of non-child bearing potential, who is either surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or post-hysterectomy) or is postmenopausal without menses for >2 years. Women who are <2 years postmenopausal are required to have menopausal status confirmed by follicle-stimulating hormone (FSH) and estradiol levels at the screening evaluation. If FSH and estradiol levels do not provide confirmation of menopause, subject will be considered to be of childbearing potential.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Diagnosis of pemphigus foliaceus, paraneoplastic pemphigus, or other autoimmune blistering disease (other than pemphigus vulgaris).
* Past or current history of hypersensitivity to components of the investigational product or medically significant adverse effects (including allergic reactions) from cetirizine (or antihistamine equivalent) or paracetamol/acetaminophen.
* Prior treatment with rituximab without achieving disease control within 6 months of initiating rituximab dosing.
* Prior treatment with immunosuppressant or immunomodulation agents within the protocol specified periods
* Evidence or history of clinically significant infections

For Japan: Evidence or history of clinically significant infection or medical condition including: Pneumocystis pneumonia or interstitial pneumonia

* Past or current malignancy, except for cervical carcinoma Stage 1B or less, noninvasive basal cell and squamous cell skin carcinoma and cancer diagnoses with a duration of complete response (remission) >5 years
* Significant concurrent, uncontrolled medical condition that could affect the subject's safety, impair the subject's reliable participation in the study, impair the evaluation of endpoints, or necessitate the use of medication not allowed by the protocol. This includes subjects who require any systemic steroid treatment for a concurrent medical condition (other than pemphigus vulgaris).
* Use of an investigational drug or other experimental therapy within 4 weeks, 5 pharmacokinetic half-lives, or the duration of biological effect (whichever is longer) prior to Screening.
* Electrocardiogram (ECG) showing a clinically significant abnormality or showing a QTc interval =450 msec (=480 msec for subjects with a bundle branch block)
* Woman who is breastfeeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/08/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/01/2018
Sample size
Target
Accrual to date
Final
35
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Novartis Investigational Site - East Melbourne
Recruitment hospital [2] 0 0
Novartis Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
3050 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Pennsylvania
Country [7] 0 0
United States of America
State/province [7] 0 0
Utah
Country [8] 0 0
Greece
State/province [8] 0 0
Thessalonica
Country [9] 0 0
Israel
State/province [9] 0 0
Ramat-Gan
Country [10] 0 0
Israel
State/province [10] 0 0
Tel Aviv
Country [11] 0 0
Italy
State/province [11] 0 0
Lombardia
Country [12] 0 0
Japan
State/province [12] 0 0
Tokyo
Country [13] 0 0
Poland
State/province [13] 0 0
Warszawa
Country [14] 0 0
Romania
State/province [14] 0 0
Cluj-Napoca

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters. Ofatumumab is a novel monoclonal antibody (mAb) that specifically binds to the human CD20 antigen, which is expressed only in B lymphocytes.

The purpose of this study was to evaluate the efficacy, tolerability, and safety of ofatumumab injection for subcutaneous use (ofatumumab SC) 20 milligrams (mg) administered once in every 4 weeks, (with an additional 20 mg loading dose \[i.e. 40 mg total\] at both Week 0 and Week 4) in subjects with PV. It was anticipated that with sustained B-cell depletion in the presence of ofatumumab SC, and the resultant reduction of pathogenic anti Dsg (desmoglein) autoantibodies in PV, that clinical remission of the disease would result.
Trial website
https://clinicaltrials.gov/study/NCT01920477
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01920477